Novartis drug cuts recurrence risk by 25% in early-stage breast cancer
By Ludwig Burger FRANKFURT (Reuters) - Novartis breast cancer drug Kisqali cut the risk of…
N2:CH
Marketmind: Fed hawks re-emerge, dollar pumped
A look at the day ahead in U.S. and global markets from Mike Dolan Amid all the…
Marketmind: Disinflation cheer, debt cap fear
A look at the day ahead in U.S. and global markets from Mike Dolan Investor relief that…
Marketmind: Cloud control – tech trumps banks
A look at the day ahead in U.S. and global markets from Mike Dolan Just as markets were…
Marketmind: Banks calm the horses
A look at the day ahead in U.S. and global markets from Mike Dolan. As U.S. banking…
Ferrari fever? Classic cars roar into investment funds
By Valentina Za and Giulio Piovaccari MILAN (Reuters) - In 1977, a Ferrari owner…
Marketmind: Banks to test soft landing thesis
A look at the day ahead in U.S. and global markets from Mike Dolan World markets have…
Lack of electric vans opens door for Chinese, other EV makers
By Nick Carey LONDON (Reuters) - Legacy automakers got off to a late start with their…
Marketmind: And it was all going so well
LONDON (Reuters) - A look at the day ahead in U.S. and global markets from Amanda Cooper.…
Markets labor under recession cloud
(Refiling to fix formatting issue.) A look at the day ahead in U.S. and global markets…